PPARA and primary biliary cholangitis: Looking specifically to the PBC setting, cumulating reports of using fenofibrate (a synthetic PPAR-alpha agonist) and bezafibrate (a pan-PPAR agonist) for the adjunctive treatment of PBC, including a variety of open-label experiences and, more recently, also randomized controlled data (for bezafibrate) [88,89,90], have progressively proposed these molecules as potential alternatives in patients presenting with inadequate response to UDCA.